Immunohistochemistry (IHC) : Formalin-fixed and paraffin-embedded human brain stained with anti-PGP 9.5 antibody using peroxidase-conjugate and DAB chromogen. Note the cytoplasmic staining of glial cells

rabbit anti-PGP9.5 monoclonal antibody (ZR401) 6331

$160.00 – $528.00

Antibody summary

Rabbit monoclonal to PGP9.5
Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
Reacts with: Human
Isotype:IgG
Control: Nerve tissue, small intestine wall (Cajal cells)
Visualization: Cytoplasmic
0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted

available sizes

Clear

SKU: 6331parent Category: antibody Tags: anatomy, monoclonal, Neuropathology/Endocrine, PGP9.5

Weight	1 lbs
Dimensions	9 × 5 × 2 in
host	mouse
isotype	IgG
clonality	monoclonal
concentration	concentrate, predilute
applications	IHC
reactivity	human
available size	0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted

rabbit anti-PGP9.5 monoclonal antibody ZR401 6331

antibody
Database link: human P09936
Tested applications IHC
Recommended dilutions Concentrated 1:100-200
Application Notes Positive control: Nerve tissue, small intestine wall (Cajal cells)
Immunogen Recombinant human carboxyl-terminal hydrolase-1
Size and concentration 7 mL prediluted or 0.1, 0.5, 1.0 mL and concentrated
Form liquid
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Purity affinity purified
Clonality monoclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit polyclonal - Isotype Control

target relevance
Protein names Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) (EC 3.4.19.12) (Neuron cytoplasmic protein 9.5) (PGP 9.5) (PGP9.5) (Ubiquitin thioesterase L1)
Gene names UCHL1,UCHL1
Protein family Peptidase C12 family
Mass 24824Da
Function FUNCTION: Deubiquitinase that plays a role in the regulation of several processes such as maintenance of synaptic function, cardiac function, inflammatory response or osteoclastogenesis (PubMed:22212137, PubMed:23359680). Abrogates the ubiquitination of multiple proteins including WWTR1/TAZ, EGFR, HIF1A and beta-site amyloid precursor protein cleaving enzyme 1/BACE1 (PubMed:22212137, PubMed:25615526). In addition, recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin to maintain a stable pool of monoubiquitin that is a key requirement for the ubiquitin-proteasome and the autophagy-lysosome pathways (PubMed:12408865, PubMed:8639624, PubMed:9774100). Regulates amyloid precursor protein/APP processing by promoting BACE1 degradation resulting in decreased amyloid beta production (PubMed:22212137). Plays a role in the immune response by regulating the ability of MHC I molecules to reach cross-presentation compartments competent for generating Ag-MHC I complexes (By similarity). Mediates the 'Lys-48'-linked deubiquitination of the transcriptional coactivator WWTR1/TAZ leading to its stabilization and inhibition of osteoclastogenesis (By similarity). Deubiquitinates and stabilizes epidermal growth factor receptor EGFR to prevent its degradation and to activate its downstream mediators (By similarity). Modulates oxidative activity in skeletal muscle by regulating key mitochondrial oxidative proteins (By similarity). Enhances the activity of hypoxia-inducible factor 1-alpha/HIF1A by abrogateing its VHL E3 ligase-mediated ubiquitination and consequently inhibiting its degradation (PubMed:25615526). {ECO:0000250\|UniProtKB:Q9R0P9, ECO:0000269\|PubMed:12408865, ECO:0000269\|PubMed:22212137, ECO:0000269\|PubMed:23359680, ECO:0000269\|PubMed:25615526, ECO:0000269\|PubMed:8639624, ECO:0000269\|PubMed:9774100}.
Catalytic activity CATALYTIC ACTIVITY: Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-residue protein attached to proteins as an intracellular targeting signal).; EC=3.4.19.12; Evidence={ECO:0000269\|PubMed:12408865, ECO:0000269\|PubMed:12705903, ECO:0000269\|PubMed:16475834, ECO:0000269\|PubMed:20439756, ECO:0000269\|PubMed:23359680, ECO:0000269\|PubMed:25615526, ECO:0000269\|PubMed:8639624, ECO:0000269\|PubMed:9774100};
Subellular location SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269\|PubMed:19261853}. Endoplasmic reticulum membrane {ECO:0000269\|PubMed:19261853}; Lipid-anchor {ECO:0000269\|PubMed:19261853}. Note=About 30% of total UCHL1 is associated with membranes in brain. Localizes near and/or within mitochondria to potentially interact with mitochondrial proteins. {ECO:0000250\|UniProtKB:Q9R0P9}.
Tissues TISSUE SPECIFICITY: Found in neuronal cell bodies and processes throughout the neocortex (at protein level). Expressed in neurons and cells of the diffuse neuroendocrine system and their tumors. Weakly expressed in ovary. Down-regulated in brains from Parkinson disease and Alzheimer disease patients. {ECO:0000269\|PubMed:14722078, ECO:0000269\|PubMed:9790970}.
Structure SUBUNIT: Monomer. Homodimer. Interacts with SNCA (By similarity). Interacts with COPS5. {ECO:0000250, ECO:0000269\|PubMed:12082530, ECO:0000269\|PubMed:16537382, ECO:0000269\|PubMed:20439756}.
Post-translational modification PTM: O-glycosylated. {ECO:0000250}.
Involvement in disease DISEASE: Parkinson disease 5 (PARK5) [MIM:613643]: A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia. {ECO:0000269\|PubMed:12408865, ECO:0000269\|PubMed:12705903, ECO:0000269\|PubMed:9774100}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.; DISEASE: Spastic paraplegia 79A, autosomal dominant, with ataxia (SPG79A) [MIM:620221]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG79A is a slowly progressive form characterized by late-onset spastic ataxia, neuropathy, and often optic atrophy. {ECO:0000269\|PubMed:35986737}. Note=The disease is caused by variants affecting the gene represented in this entry.; DISEASE: Spastic paraplegia 79B, autosomal recessive (SPG79B) [MIM:615491]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG79B is characterized by childhood onset blindness, cerebellar ataxia, nystagmus, dorsal column dysfunction, and spasticity with upper motor neuron dysfunction. {ECO:0000269\|PubMed:23359680, ECO:0000269\|PubMed:28007905}. Note=The disease is caused by variants affecting the gene represented in this entry.
Target Relevance information above includes information from UniProt accession: P09936
The UniProt Consortium

Data

Formalin-fixed and paraffin-embedded human brain stained with anti-PGP 9.5 antibody using peroxidase-conjugate and DAB chromogen. Note the cytoplasmic staining of glial cells

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.